Cargando…

Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer

Systemic treatment of hormone receptor-positive (HR+) breast cancer is undergoing a renaissance, with a number of targeted therapies including CDK4/6, mTOR, and PI3K inhibitors now approved for use in combination with endocrine therapies. The increased use of targeted therapies has changed the natur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Freelander, Allegra, Brown, Lauren J., Parker, Andrew, Segara, Davendra, Portman, Neil, Lau, Brandon, Lim, Elgene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922594/ https://www.ncbi.nlm.nih.gov/pubmed/33671468 http://dx.doi.org/10.3390/genes12020285

Ejemplares similares

Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic
por: Kumar, Sanjeev, et al.
Publicado: (2021)

Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status
por: Downton, Teesha, et al.
Publicado: (2022)

MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer
por: Portman, Neil, et al.
Publicado: (2021)

CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
por: Zhou, Fiona H., et al.
Publicado: (2023)

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
por: Portman, Neil, et al.
Publicado: (2020)

Epigenetic Therapies and Biomarkers in Breast Cancer
por: Brown, Lauren Julia, et al.
Publicado: (2022)

Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review
por: Haggstrom, Lucy R., et al.
Publicado: (2022)

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
por: Karimi, Leena, et al.
Publicado: (2023)

Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
por: Yi, Zongbi, et al.
Publicado: (2017)

Renewed interest in the progesterone receptor in breast cancer
por: Lim, Elgene, et al.
Publicado: (2016)

Case Report: Paclitaxel-Induced Pneumonitis in Early Breast Cancer: A Single Institution Experience and Review
por: Ardolino, Luke, et al.
Publicado: (2021)

Messina: A Novel Analysis Tool to Identify Biologically Relevant Molecules in Disease
por: Pinese, Mark, et al.
Publicado: (2009)

Genetics, Treatment, and New Technologies of Hormone Receptor-Positive Breast Cancer
por: Sebastian, William, et al.
Publicado: (2023)

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
por: Brett, Jamie O., et al.
Publicado: (2021)

Why ethics guidance needs to be updated for contemporary HIV prevention research
por: Brown, Brandon J, et al.
Publicado: (2020)

(64)Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial
por: Wong, Keith, et al.
Publicado: (2022)

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
por: Keenan, Tanya E., et al.
Publicado: (2021)

Hormonal Function and the Kidney. Volume 4. Contemporary Issues in Nephrology
por: Black, Henry R.
Publicado: (1980)

Hormone-Producing Tumours of the Gastrointestinal Tract - Contemporary Issues in Gastroenterolgy
por: Ahmed, Syed Rafeeq
Publicado: (1986)

The Immunology of Hormone Receptor Positive Breast Cancer
por: Goldberg, Jonathan, et al.
Publicado: (2021)

The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms
por: Belčič Mikič, Tanja, et al.
Publicado: (2021)

Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials
por: Brown, Lauren J., et al.
Publicado: (2021)

A Contemporary Review of Molecular Therapeutic Targets for Adenoid Cystic Carcinoma
por: Miller, Lauren E., et al.
Publicado: (2022)

Biomarkers of Hypochromia: The Contemporary Assessment of Iron Status and Erythropoiesis
por: Urrechaga, Eloísa, et al.
Publicado: (2013)

Immunotherapy biomarkers for HCC: contemporary challenges and emerging opportunities
por: Kwee, Sandi, et al.
Publicado: (2022)

Contemporary Biomarkers for Renal Transplantation: A Narrative Overview
por: Novacescu, Dorin, et al.
Publicado: (2023)

Molecular vulnerabilities and therapeutic resistance in hormone receptor positive and HER2 dependent breast cancer tumours
por: Velaga, Ravi, et al.
Publicado: (2022)

Precision Medicine in Hormone Receptor-Positive Breast Cancer
por: Nasrazadani, Azadeh, et al.
Publicado: (2018)

Cannabinoids and Hormone Receptor-Positive Breast Cancer Treatment
por: Dobovišek, Luka, et al.
Publicado: (2020)

Molecular biology of steroid and nuclear hormone receptors /
Publicado: (1998)

Efficacy of chemotherapy after hormone therapy for hormone receptor–positive metastatic breast cancer
por: Mori, Ryutaro, et al.
Publicado: (2014)

Molecular profiling in contemporary breast cancer management
por: Davey, Matthew G, et al.
Publicado: (2023)

Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture
por: Wilson, Hannah C.P., et al.
Publicado: (2015)

Sex impacts cardiac function and the proteome response to thyroid hormone in aged mice
por: Zhu, Wei Zhong, et al.
Publicado: (2020)

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers
por: Yi, Zongbi, et al.
Publicado: (2020)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2021)

Contemporary Poetry and Contemporary Science
por: Crawford, Robert
Publicado: (2006)

The contemporary role and impact of urine-based biomarkers in bladder cancer
por: Duquesne, Igor, et al.
Publicado: (2017)

Biomarkers of non-communicable chronic disease: an update on contemporary methods
por: Al-hadlaq, Solaiman M., et al.
Publicado: (2022)

Hematologic Malignancies of the Breast: A Contemporary Series Investigating Incidence, Presentation, Accuracy of Diagnosis on Core Needle Biopsy, and Hormone Receptor Expression
por: Guilbert, Marie-Christine, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_orbjk37maitmncnc2cjl443s9c